Loretta L. Nielsen

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2007 · 698 citations

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

Asra Mirza, Marnie McGuirk, Tish Hockenberry et al. · Oncogene · 2002 · 534 citations · Full text

Tumor Biology, Wild-type P53, P53-dependent Apoptotic Pathway +6

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

Orville Kolterman, Dennis Dong Hwan Kim, Larry Z. Shen et al. · American Journal of Health-System Pharmacy · 2005 · 434 citations

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Ming Liu, Matthew Bryant, Jianping Chen et al. · PubMed · 1998 · 309 citations

Sch 66336, Chemoprevention Strategy, Farnesyl Protein Transferase +15

Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes

Frauke Fehse, Michael Trautmann, Jens J. Holst et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 298 citations · Full text